ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $32.13.

A number of equities research analysts have recently weighed in on the company. Robert W. Baird started coverage on ACADIA Pharmaceuticals in a research note on Tuesday, January 30th. They set an “outperform” rating and a $40.00 price target on the stock. TheStreet raised shares of ACADIA Pharmaceuticals from a “d” rating to a “c” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. decreased their price target on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an “overweight” rating for the company in a report on Monday, March 25th. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $37.00 target price on shares of ACADIA Pharmaceuticals in a research note on Tuesday.

Insider Activity at ACADIA Pharmaceuticals

In other news, CEO Stephen Davis sold 5,577 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $24.67, for a total transaction of $137,584.59. Following the sale, the chief executive officer now owns 101,890 shares of the company’s stock, valued at approximately $2,513,626.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Stephen Davis sold 5,577 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $24.67, for a total transaction of $137,584.59. Following the sale, the chief executive officer now directly owns 101,890 shares of the company’s stock, valued at approximately $2,513,626.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Mark C. Schneyer sold 5,434 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $17.90, for a total value of $97,268.60. Following the sale, the chief financial officer now owns 26,183 shares in the company, valued at $468,675.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,116 shares of company stock worth $1,625,639. 27.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mutual of America Capital Management LLC acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $2,206,000. Qube Research & Technologies Ltd lifted its stake in ACADIA Pharmaceuticals by 757.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 212,919 shares of the biopharmaceutical company’s stock valued at $4,437,000 after buying an additional 188,080 shares in the last quarter. RTW Investments LP lifted its stake in ACADIA Pharmaceuticals by 18.3% in the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock valued at $241,255,000 after buying an additional 1,793,288 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in ACADIA Pharmaceuticals by 9.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,073,093 shares of the biopharmaceutical company’s stock worth $22,363,000 after buying an additional 91,641 shares during the last quarter. Finally, Northern Trust Corp increased its stake in ACADIA Pharmaceuticals by 4.9% during the 3rd quarter. Northern Trust Corp now owns 1,220,677 shares of the biopharmaceutical company’s stock worth $25,439,000 after buying an additional 57,555 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Down 0.2 %

Shares of ACAD opened at $17.05 on Friday. The company has a 50 day moving average of $19.15 and a two-hundred day moving average of $23.33. ACADIA Pharmaceuticals has a twelve month low of $16.16 and a twelve month high of $33.99. The company has a market cap of $2.82 billion, a price-to-earnings ratio of -44.87 and a beta of 0.42.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The business had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. During the same period in the previous year, the business earned ($0.26) EPS. The firm’s revenue for the quarter was up 69.3% compared to the same quarter last year. On average, sell-side analysts expect that ACADIA Pharmaceuticals will post 0.62 EPS for the current year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.